Sector News

Relay adds execs as it transitions to the development stage

December 5, 2018
Life sciences

Former Fierce 15 winner Relay Therapeutics has brought on Verastem’s Mahesh Padval, Ph.D., and Eli Lilly’s Mary Mader, Ph.D., to boost its drug discovery and development operations in oncology as it begins to transition to an R&D-stage biotech.

Padval was appointed as Relay’s senior VP of pharmaceutical drug development, while Mader was named VP of chemistry.

At Verastem, Padval served as VP of pharmaceutical sciences and product development, helping to oversee preclinical development, CMC and clinical pharmacology activities—including for the September approval and launch of Copiktra in third-line chronic lymphocytic leukemia, small lymphocytic leukemia and follicular lymphoma, which is expected to reach between $500 million and $850 million in peak sales.

Prior to Verastem, Padval was VP of preclinical development and formulations at Zalicus, and he also held roles at Charles River Discovery and Development Services and Genzyme Transgenics.

Mader previously served as a senior research advisory and a research fellow at Eli Lilly, where she worked on the discovery and development of multiple clinical candidates. Before that, she was a visiting research scientist at the Bayer Research Center and an associate professor at Grinnell College in Iowa.

Relay’s pipeline focuses on studying the movement of proteins within cells in real-time. Its discovery engine examines the full mobility of a protein and the ways that motion can regulate function.

The company’s head of R&D, Don Bergstrom, M.D., Ph.D., said the company plans to expand its protein motion platform to an “expanding array of therapeutic targets” as it transitions to the development stage.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach